LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro to Report Financial Results for First Quarter 2021 on May 6
April 29, 2021 16:05 ET | Recro Pharma, Inc.
MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences
April 15, 2021 07:00 ET | Recro Pharma, Inc.
GAINESVILLE, Ga., April 15, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Inducement Grants for New Staff
April 06, 2021 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Strengthens Business Development Team to Drive Customer Growth and Diversification
April 05, 2021 07:00 ET | Recro Pharma, Inc.
Six Recent Hires Provide Broader Coverage and Expanded Capabilities in the Areas of Sales and Marketing Significant Traction Already Achieved in First Months of 2021 MALVERN, Pa., April 05, 2021 ...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro to Present at H.C. Wainwright Global Life Science Conference
March 02, 2021 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Fourth Quarter and Year End 2020 Financial Results
February 26, 2021 07:00 ET | Recro Pharma, Inc.
Strengthened Industry-Centric Leadership Reorganization Initiated to Enhance Operations as Recro Expands Customer Portfolio, Explores Inorganic Growth Opportunities Core Commercial Product Outlook...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced
February 23, 2021 16:05 ET | Recro Pharma, Inc.
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Announces Amendment to Athyrium Credit Facility
February 23, 2021 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26
February 19, 2021 16:05 ET | Recro Pharma, Inc.
MALVERN, Pa., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
recro_logo.jpg
Recro Strengthens Leadership Team With Key Executive and Board Appointments
February 11, 2021 07:00 ET | Recro Pharma, Inc.
Company Names CDMO Industry Thought Leader, Jim Miller, to Board of Directors and Selects Ryan D. Lake as Dedicated Chief Financial OfficerRecent Appointments, including CEO David Enloe, Provide...